EcoR1 Capital
Latest statistics and disclosures from EcoR1 Capital's latest quarterly 13F-HR filing:
- Top 5 stock holdings are APLS, PRTA, ARVN, SRPT, CRNX, and represent 42.37% of EcoR1 Capital's stock portfolio.
- Added to shares of these 10 stocks: SRPT (+$141M), CRNX (+$100M), CRSP (+$95M), MORF (+$77M), ADAP (+$43M), CLDX (+$27M), Lenz Therapeutics (+$27M), NKTX (+$22M), PCVX (+$21M), MDGL (+$20M).
- Started 16 new stock positions in ADAP, MDGL, DYN, NKTX, Lenz Therapeutics, ALVR, KROS, RNA, Kyverna Therapeutics, ARQT. CLDX, ALPN, CRSP, PRME, PCVX, KOD.
- Reduced shares in these 10 stocks: Mirati Therapeutics (-$435M), ARGX (-$115M), EWTX (-$41M), Graphite Bio (-$22M), SYRE (-$19M), RVMD, AVIR, NGM, ALLK, TYRA.
- Sold out of its positions in SYRE, ALLK, ARGX, Graphite Bio, Mirati Therapeutics, NGM, PHAT, RVMD, TYRA, NAMSW.
- EcoR1 Capital was a net buyer of stock by $47M.
- EcoR1 Capital has $4.0B in assets under management (AUM), dropping by 2.65%.
- Central Index Key (CIK): 0001587114
Tip: Access up to 7 years of quarterly data
Positions held by EcoR1 Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for EcoR1 Capital
EcoR1 Capital holds 57 positions in its portfolio as reported in the March 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Apellis Pharmaceuticals (APLS) | 16.9 | $668M | 11M | 58.78 |
|
|
| Prothena Corp SHS (PRTA) | 7.3 | $287M | 12M | 24.77 |
|
|
| Arvinas Ord (ARVN) | 7.0 | $278M | 6.7M | 41.28 |
|
|
| Sarepta Therapeutics (SRPT) | 6.3 | $249M | +130% | 1.9M | 129.46 |
|
| Crinetics Pharmaceuticals In (CRNX) | 4.9 | $195M | +106% | 4.2M | 46.81 |
|
| Galapagos Nv Spon Adr (GLPG) | 4.7 | $185M | 5.8M | 32.20 |
|
|
| Anaptysbio Inc Common (ANAB) | 4.3 | $169M | 7.5M | 22.52 |
|
|
| Zymeworks Del (ZYME) | 3.6 | $141M | 13M | 10.52 |
|
|
| Kura Oncology (KURA) | 3.5 | $139M | +12% | 6.5M | 21.33 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 3.1 | $122M | 1.0M | 120.42 |
|
|
| Xencor (XNCR) | 3.0 | $118M | 5.3M | 22.13 |
|
|
| ACADIA Pharmaceuticals (ACAD) | 2.8 | $111M | 6.0M | 18.49 |
|
|
| Tango Therapeutics (TNGX) | 2.7 | $106M | 13M | 7.94 |
|
|
| Immunome (IMNM) | 2.4 | $96M | 3.9M | 24.68 |
|
|
| Crispr Therapeutics Namen Akt (CRSP) | 2.4 | $95M | NEW | 1.4M | 68.16 |
|
| Mersana Therapeutics (MRSN) | 2.2 | $87M | 19M | 4.48 |
|
|
| Morphic Hldg (MORF) | 2.1 | $84M | +1028% | 2.4M | 35.20 |
|
| Nuvation Bio Com Cl A (NUVB) | 1.8 | $70M | 19M | 3.64 |
|
|
| Neurogene (NGNE) | 1.6 | $65M | 1.3M | 50.90 |
|
|
| Centessa Pharmaceuticals Sponsored Ads (CNTA) | 1.6 | $64M | 5.6M | 11.30 |
|
|
| Oric Pharmaceuticals (ORIC) | 1.2 | $47M | 3.4M | 13.75 |
|
|
| Adaptimmune Therapeutics Sponds Adr (ADAP) | 1.1 | $43M | NEW | 27M | 1.58 |
|
| Tscan Therapeutics (TCRX) | 1.0 | $40M | 5.0M | 7.94 |
|
|
| Voyager Therapeutics (VYGR) | 0.9 | $37M | 3.9M | 9.31 |
|
|
| Third Harmonic Bio (THRD) | 0.8 | $30M | 3.2M | 9.44 |
|
|
| Neumora Therapeutics (NMRA) | 0.7 | $29M | 2.1M | 13.75 |
|
|
| Celldex Therapeutics Com New (CLDX) | 0.7 | $27M | NEW | 650k | 41.97 |
|
| Iteos Therapeutics (ITOS) | 0.7 | $27M | +79% | 2.0M | 13.64 |
|
| Lenz Therapeutics Com Added | 0.7 | $27M | NEW | 1.2M | 22.33 |
|
| Atea Pharmaceuticals (AVIR) | 0.6 | $25M | -12% | 6.1M | 4.04 |
|
| Alector (ALEC) | 0.6 | $24M | 4.1M | 6.02 |
|
|
| Edgewise Therapeutics (EWTX) | 0.6 | $23M | -64% | 1.3M | 18.24 |
|
| Nkarta (NKTX) | 0.5 | $22M | NEW | 2.0M | 10.81 |
|
| Pharvaris N V (PHVS) | 0.5 | $21M | 900k | 23.11 |
|
|
| Vaxcyte (PCVX) | 0.5 | $21M | NEW | 300k | 68.31 |
|
| Madrigal Pharmaceuticals (MDGL) | 0.5 | $20M | NEW | 75k | 267.04 |
|
| Avidity Biosciences Ord (RNA) | 0.5 | $19M | NEW | 758k | 25.52 |
|
| Ovid Therapeutics (OVID) | 0.5 | $19M | 6.1M | 3.05 |
|
|
| Verve Therapeutics (VERV) | 0.4 | $17M | 1.3M | 13.28 |
|
|
| Keros Therapeutics (KROS) | 0.3 | $12M | NEW | 188k | 66.20 |
|
| Dyne Therapeutics (DYN) | 0.3 | $12M | NEW | 427k | 28.39 |
|
| Kyverna Therapeutics Com Added | 0.3 | $11M | NEW | 450k | 24.84 |
|
| Gossamer Bio (GOSS) | 0.3 | $11M | 9.2M | 1.18 |
|
|
| Kodiak Sciences (KOD) | 0.2 | $8.8M | NEW | 1.7M | 5.26 |
|
| Allovir (ALVR) | 0.2 | $8.5M | NEW | 11M | 0.75 |
|
| Generation Bio (GBIO) | 0.2 | $8.3M | 2.0M | 4.07 |
|
|
| Atara Biotherapeutics (ATRA) | 0.2 | $7.1M | 10M | 0.69 |
|
|
| Proqr Thrapeutics N V Shs Euro (PRQR) | 0.2 | $6.6M | -3% | 2.9M | 2.29 |
|
| Aligos Therapeutics (ALGS) | 0.2 | $6.3M | 6.4M | 0.98 |
|
|
| Arcutis Biotherapeutics (ARQT) | 0.1 | $5.0M | NEW | 500k | 9.91 |
|
| Prime Medicine (PRME) | 0.1 | $4.9M | NEW | 700k | 7.00 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.1 | $3.5M | 963k | 3.64 |
|
|
| Hookipa Pharma Inc equity (HOOK) | 0.1 | $3.3M | 4.6M | 0.71 |
|
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.0M | 67k | 15.71 |
|
|
| Pmv Pharmaceuticals (PMVP) | 0.0 | $964k | 567k | 1.70 |
|
|
| Caremax *w Exp 06/08/202 (CMAXW) | 0.0 | $482k | 100k | 4.82 |
|
|
| Alpine Immune Sciences (ALPN) | 0.0 | $40k | NEW | 1.0k | 39.64 |
|
Past Filings by EcoR1 Capital
SEC 13F filings are viewable for EcoR1 Capital going back to 2014
- EcoR1 Capital 2024 Q1 filed May 15, 2024
- EcoR1 Capital 2023 Q4 filed Feb. 14, 2024
- EcoR1 Capital 2023 Q3 filed Nov. 14, 2023
- EcoR1 Capital 2023 Q2 filed Aug. 14, 2023
- EcoR1 Capital 2023 Q1 filed May 15, 2023
- EcoR1 Capital 2022 Q4 filed Feb. 14, 2023
- EcoR1 Capital 2022 Q3 filed Nov. 14, 2022
- EcoR1 Capital 2022 Q2 filed Aug. 15, 2022
- EcoR1 Capital 2022 Q1 filed May 16, 2022
- EcoR1 Capital 2021 Q4 filed Feb. 14, 2022
- EcoR1 Capital 2021 Q3 restated filed Nov. 22, 2021
- EcoR1 Capital 2021 Q3 filed Nov. 15, 2021
- EcoR1 Capital 2021 Q2 filed Aug. 16, 2021
- EcoR1 Capital 2021 Q1 filed May 17, 2021
- EcoR1 Capital 2020 Q4 filed Feb. 16, 2021
- EcoR1 Capital 2020 Q3 filed Nov. 16, 2020